Philadelphia, PA (PRWEB) June 20, 2014
Privately held early-stage Pennsylvania-based therapeutic companies just got a “leg up” for their capital raise. Through the recently announced JumpStart Grant, early stage therapeutic companies are competing for professional services and expertise in the form of product development and commercialization plans. A detailed, comprehensive and well-conceived development plan, including a viable commercial plan, is critical to raising venture rounds and executing efficiently. Category innovation frequently derives from scientists with profound therapeutic or drug discovery expertise; unfortunately, they usually possess less comprehensive development, regulatory, or commercial expertise and don’t have the funds to engage large consulting companies to help them. The Jump Start Grant is aimed at filling this void for early-stage companies.
“Early stage companies often lack the expertise to comprehensively address the myriad commercial development challenges which exist in the life sciences marketplace,” said Christopher P. Molineaux, President & CEO, Pennsylvania Bio. “We are fortunate to have partnered with two industry leaders on this unique grant opportunity which gives our members access to development and commercialization insights required for preparation of funding applications and presentations.”
Subject matter experts will assess applications based on the following submission criteria: Concept, Scientific Rationale, Innovation, Market Opportunity Understanding, Management Team, and Overall Impact. Two winners will receive service grants that include an additive development plan and budget, associated GANTT charts, and commercial opportunity assessment and budget.
Michelle Higgin, PhD, Principle of PharmaDirections and Jennifer Filbey, PhD, President of New Perspectives expressed that their organizations are proud to be working with PA Bio to offer this unique opportunity for two of the regions’ most exciting and innovative companies. “Helping companies with practical solutions to advance their programs and get their products closer to the market and benefiting patients is rewarding for all of us,” said Michelle Higgin .
Applications open today and are due no later than August 21, 2014. Winners will be announced in October 2014 at PA Bio’s Life Sciences Future Signature Event. Interested leadership teams can review application requirements, relevant timelines, and eligibility rules at http://www.newperspectives-us.com or http://www.PharmaDirections.com.
About New Perspectives:
New Perspectives specializes in helping emerging specialty pharma and biotech companies enter the U.S. market to commercialize their assets, whether through a "take-to-market" product launch strategy or a product "license" or acquisition. We are seasoned veterans of the pharmaceutical and biotech industries who have started and sold our own companies, launched biotech companies, and worked in traditional large and small pharmaceutical/biotech companies. We provide strategic leadership and operational expertise in the essential building blocks of the U.S. market and new product launches (NCE and 505B2) such as Marketing Strategy, Managed Access and Reimbursement, Commercial Operations, and U.S. Corporate Set-up. We operate as your contract commercial team until the product development and commercialization risks warrant an internal team.
PharmaDirections, Inc. is a pharmaceutical project management and consulting group focused on CMC (Chemistry, Manufacturing and Controls), formulation development, preclinical and regulatory affairs. PharmaDirections focuses exclusively on working with virtual pharmaceutical companies who outsource their R&D efforts. We direct virtual contract research using experts in all aspects of drug development who provide both the intellectual oversight and the execution capabilities for any drug development activity.
About Pennsylvania Bio
Pennsylvania Bio is the state-wide trade association for the life sciences in Pennsylvania and serves as a catalyst to ensure Pennsylvania is the global leader in the life sciences by creating a cohesive community that unites our biotechnology, medical device, diagnostic, pharmaceutical, research, and financial strengths. More information is available at http://www.pabio.org.